Previous 10 | Next 10 |
home / stock / argnf / argnf news
$ 1 7 3 million in fourth quarter and $ 401 million in full year 2022 VYVGART® (efgartigimod alfa- fcab ) global net product sales FDA review ongoing for SC efgartigimod BLA with PDUFA target action date of June 20, 2023...
February 27, 2023 Amsterdam , the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders h...
February 2 7 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participa...
Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund gained 14.85% (Institutional Shares) during the final quarter of 2022. We enter...
Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended December 31, 2022, Baron Health Care Fund rose 9.08% (Institutional Shares) vs. the 11.54% gai...
Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. The Fund was down 7.1% (Institutional Shares) during the fourth quarter, compared to a gain of 2.2% for the Russell...
February 23 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webc...
January 27 , 202 3 Amsterdam , the Netherlands — argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (F...
Summary Argenx caught a strong bid in FY22 on the back of advancements in its Efgartigimod [Vyvgart] pipeline for Myasthenia Gravis. Demand began to fade rolling into the new year, with heavy outflows across the 3-months to-date. The company reported strong results in its Vyvgart se...
January 16 , 202 3 Amsterdam , the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareh...
News, Short Squeeze, Breakout and More Instantly...
July 18, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, Ju...
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study July 16, 2024 6:30am CET Amsterdam, the Netherlands— ...
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) , w...